Late last year, the therapy developers dosed their first patient following positive preclinical data demonstrating safety and ...

Intellia will present additional data from the ongoing Phase 1/2 study in an oral presentation at the European Academy of ...

Af­ter work­ing off $20 mil­lion in seed fund­ing for about four years, HAYA Ther­a­peu­tics tapped the fund­ing well and ...